Objective To discuss the pathogenesis of severe coronavirus disease 2019 (COVID-19)
infection and the pharmacological effects of glucocorticoids (GCs) toward this infection. To …

Prolonged, low-dose glucocorticoids (GCs) have shown the highest efficacy among
pharmacological and non-pharmacological treatments for COVID-19. Despite the World …

Abstract Coronavirus disease 2019 (COVID-19) is a viral pneumonia that can lead to acute
respiratory distress syndrome (ARDS). Until the commercialization of a vaccine …

In the realm of acute respiratory infections, coronavirus disease-19 (COVID-19), caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a global public …

Background Glucocorticoids are widely used in the treatment of various pulmonary
inflammatory diseases, but they are also often accompanied by significant adverse …

Background It is unclear the efficacy and safety of glucocorticoids compared with placebo or
usual care for treatment of COVID-19. Research design and methods Randomized …

Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus
SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health …

Severe infection of COVID-19 is characterized by an excessive inflammatory response in a
form of a storm of proinflammatory cytokines leading to severe lung injury and life …

Background Currently, some meta-analyses on COVID-19 have suggested that
glucocorticoids use can reduce the mortality rate of COVID-19 patients, utilization rate of …

Coronavirus disease 2019 (COVID-19) pneumonia caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant mortality in pandemic …